keyword
MENU ▼
Read by QxMD icon Read
search

CALGB

keyword
https://www.readbyqxmd.com/read/29781235/most-patients-are-eligible-for-an-alternative-to-conventional-whole-breast-irradiation-for-early-stage-breast-cancer-a-national-cancer-database-analysis
#1
Ehsan H Balagamwala, Bindu V Manyam, Charles Marc Leyrer, Naveen Karthik, Timothy Smile, Rahul D Tendulkar, Sheen Cherian, Diane Radford, Zahraa Al-Hilli, Frank Vicini, Chirag Shah
We evaluated the proportion of patients eligible for alternatives to standard whole breast irradiation (WBI) following breast-conserving surgery using the National Cancer Database (NCDB). Using the 2016 dataset, Stage I-III patients were identified. Eligibility for hypofractionated WBI (HFRT), accelerated partial breast irradiation (APBI) and endocrine therapy (ET-alone) was defined using eligibility from large clinical trials as well as consensus guidelines. For patients with pN0 breast cancer, 20.6% and 37...
May 20, 2018: Breast Journal
https://www.readbyqxmd.com/read/29710284/association-of-survival-with-adherence-to-the-american-cancer-society-nutrition-and-physical-activity-guidelines-for-cancer-survivors-after-colon-cancer-diagnosis-the-calgb-89803-alliance-trial
#2
Erin L Van Blarigan, Charles S Fuchs, Donna Niedzwiecki, Sui Zhang, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L Giovannucci, Kimmie Ng, Jeffrey A Meyerhardt
Importance: The American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors (ACS guidelines) include maintaining (1) a healthy body weight; (2) physical activity; and (3) a diet that includes vegetables, fruits, and whole grains. It is not known whether patients with colon cancer who follow these guidelines have improved survival. Objective: To examine whether a lifestyle consistent with the ACS guidelines is associated with improved survival rates after colon cancer...
April 12, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29608967/time-to-treatment-failure-and-related-outcomes-among-1000-advanced-non-small-cell-lung-cancer-patients-comparisons-between-older-versus-younger-patients
#3
Ajeet Gajra, Tyler J Zemla, Aminah Jatoi, Josephine L Feliciano, Melisa L Wong, Hongbin Chen, Ronald Maggiore, Ryan P McMurray, Arti Hurria, Hyman B Muss, Harvey J Cohen, Jacqueline Lafky, Martin J Edelman, Rogerio Lilenbaum, Jennifer G Le-Rademacher
BACKGROUND: Time-to-treatment-failure (TTF) is the interval from chemotherapy initiation to premature discontinuation. We evaluated TTF based on age. METHODS: Pooled analyses were conducted with, first-line chemotherapy trials for advanced non-small cell lung cancer (CALGB 9730, 30203, and 30801). Comparisons -- with age 65+ and 70+ years -- were performed for TTF (primary endpoint), reasons for early chemotherapy cessation, grade 3+ adverse events, and overall survival...
March 30, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29602735/the-preference-to-receive-chemotherapy-and-cancer-related-outcomes-in-older-adults-with-breast-cancer-calgb-49907-alliance
#4
Ajeet Gajra, Linda McCall, Hyman B Muss, Harvey J Cohen, Aminah Jatoi, Karla V Ballman, Ann H Partridge, Linda Sutton, Barbara A Parker, Gustav Magrinat, Heidi D Klepin, Jacqueline M Lafky, Arti Hurria
OBJECTIVE: Chemotherapy preference refers to a patient's interest in receiving chemotherapy. This study examined whether chemotherapy preference was associated with toxicity, efficacy, quality of life (QoL), and functional outcomes during and after completion of adjuvant chemotherapy in older women with breast cancer. MATERIALS AND METHODS: This study is a secondary analysis of CALGB 49907, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine in patients age 65 years or older with breast cancer...
March 28, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29595113/impact-of-primary-tumor-location-on-first-line-bevacizumab-or-cetuximab-in-metastatic-colorectal-cancer
#5
Matthew Snyder, Sal Bottiglieri, Khaldoun Almhanna
Colorectal cancer is one of the most common malignancies in the United States, with a large proportion of patients presenting with metastatic disease or developing a recurrence. Systemic chemotherapy is the mainstay of therapy in this setting. There is a clear benefit in the addition of bevacizumab or cetuximab (for rat sarcoma [RAS] wild type tumors) to oxaliplatin- and irinotecan-based regimens can be considered for first-line therapy. However, many significant questions remain as to which agent reflects best practice...
March 27, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/29489431/calgb-80101-and-the-final-call-for-preoperative-chemotherapy-in-gastric-cancer
#6
Lorenzo Fornaro, Mario Scartozzi, Giuseppe Aprile
No abstract text is available yet for this article.
April 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29489429/nut-consumption-and-survival-in-patients-with-stage-iii-colon-cancer-results-from-calgb-89803-alliance
#7
Temidayo Fadelu, Sui Zhang, Donna Niedzwiecki, Xing Ye, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al B Benson, Daniel M Atienza, Michael Messino, Hedy L Kindler, Alan Venook, Shuji Ogino, Kimmie Ng, Kana Wu, Walter Willett, Edward Giovannucci, Jeffrey Meyerhardt, Ying Bao, Charles S Fuchs
Purpose Observational studies have reported increased colon cancer recurrence and mortality in patients with states of hyperinsulinemia, including type 2 diabetes, obesity, sedentary lifestyle, and high glycemic load diet. Nut intake has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, the effect of nut intake on colon cancer recurrence and survival is not known. Patients and Methods We conducted a prospective, observational study of 826 eligible patients with stage III colon cancer who reported dietary intake on food frequency questionnaires while enrolled onto a randomized adjuvant chemotherapy trial...
April 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29487024/phase-1-study-of-accelerated-hypofractionated-radiation-therapy-with-concurrent-chemotherapy-for-stage-iii-non-small-cell-lung-cancer-calgb-31102-alliance
#8
James J Urbanic, Xiaofei Wang, Jeffrey A Bogart, Thomas E Stinchcombe, Lydia Hodgson, Steven E Schild, Lyudmila Bazhenova, Olwen Hahn, Ravi Salgia, Everett E Vokes
PURPOSE: To investigate the safety of accelerated hypofractionated radiation therapy (AHRT) with concurrent chemotherapy (CT) for inoperable stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The primary objectives were to define the maximally tolerable course of accelerated radiation therapy and to describe toxicities of therapy. Total radiation therapy remained at 60 Gy. The number of once-daily fractions in each successive cohort was reduced as follows: cohort 1, 60 Gy in 27 fractions; cohort 2, 60 Gy in 24 fractions; cohort 3, 60 Gy in 22 fractions; and cohort 4, 60 Gy in 20 fractions...
May 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29390097/phase-ii-trial-of-galiximab-anti-cd80-monoclonal-antibody-plus-rituximab-calgb-50402-follicular-lymphoma-international-prognostic-index-flipi-score-is-predictive-of-upfront-immunotherapy-responsiveness
#9
M S Czuczman, J P Leonard, S Jung, J L Johnson, E D Hsi, J C Byrd, B D Cheson
No abstract text is available yet for this article.
January 29, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29358223/marine-%C3%AF-3-polyunsaturated-fatty-acid-and-fish-intake-after-colon-cancer-diagnosis-and-survival-calgb-89803-alliance
#10
Erin L Van Blarigan, Charles S Fuchs, Donna Niedzwiecki, Xing Ye, Sui Zhang, Mingyang Song, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Shuji Ogino, Edward L Giovannucci, Jeffrey A Meyerhardt
Background: Marine ω-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. Methods: We examined marine ω-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in Cancer and Leukemia Group B 89803 between 1999 and 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS)...
April 2018: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29278617/genome-wide-meta-analyses-identifies-novel-taxane-induced-peripheral-neuropathy-associated-loci
#11
Lara E Sucheston-Campbell, Alyssa I Clay-Gilmour, William E Barlow, G Thomas Budd, Daniel O Stram, Christopher A Haiman, Xin Sheng, Li Yan, Gary Zirpoli, Song Yao, Chen Jiang, Kouros Owzar, Dawn Hershman, Kathy S Albain, Daniel F Hayes, Halle C Moore, Timothy J Hobday, James A Stewart, Abbas Rizvi, Claudine Isaacs, Muhammad Salim, Jule R Gralow, Gabriel N Hortobagyi, Robert B Livingston, Deanna L Kroetz, Christine B Ambrosone
OBJECTIVE: Taxane containing chemotherapy extends survival for breast cancer patients. However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or effectively treated. Using genome-wide analyses, we sought to identify common risk variants for TIPN. PATIENTS AND METHODS: Women with high-risk breast cancer enrolled in SWOG 0221 were genotyped using the Illumina 1M chip. Genome-wide analyses were performed in relation to ≥grade 3 Common Terminology Criteria for Adverse Events (CTCAE) neuropathy in European and African Americans...
February 2018: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/29233548/the-impact-of-actual-body-weight-based-chemotherapy-dosing-and-body-size-on-adverse-events-and-outcome-in-older-patients-with-breast-cancer-results-from-cancer-and-leukemia-group-b-calgb-trial-49907-alliance-a151436
#12
Vicki A Morrison, Linda McCall, Hyman B Muss, Aminah Jatoi, Harvey J Cohen, Constance T Cirrincione, Jennifer A Ligibel, Jacqueline M Lafky, Arti Hurria
OBJECTIVE: Actual weight-based (AWB) chemotherapy dosing is recommended for obese patients in the 2012 ASCO Clinical Practice Guideline. CALGB 49907, which utilized ABW-based adjuvant chemotherapy dosing, was a phase 3 trial in women age≥65years with early stage breast cancer, providing the opportunity to examine impact of such dosing on toxicities and outcome in older patients with breast cancer. MATERIALS AND METHODS: Adverse event data were available for 615 of 633 enrolled patients...
December 7, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29168112/treatment-patterns-and-outcomes-in-patients-with-kras-wild-type-metastatic-colorectal-cancer-treated-in-first-line-with-bevacizumab-or-cetuximab-containing-regimens
#13
Arthur C Houts, Sarika Ogale, Nicolas Sommer, Sacha Satram-Hoang, Mark S Walker
PURPOSE: Patients with Kirsten rat sarcoma viral oncogene wild-type (KRAS WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) plus standard chemo backbones had comparable outcomes in phase III Cancer and Leukemia Group B (CALGB) 80405. We examined comparative effectiveness of B and C regimens in real-world community settings. METHODS: This retrospective study examined progression-free survival (PFS) and OS in a US community sample of KRAS WT mCRC patients treated with first-line B (n = 254) or C (n = 146) regimens...
November 22, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29093755/unique-amplification-of-bcr-abl1-gene-fusion-in-a-case-of-t-cell-acute-lymphoblastic-leukemia
#14
Rima Koka, Najeebah A Bade, Edward A Sausville, Yi Ning, Ying Zou
Background: ABL1 gene translocations can be seen in precursor T-acute lymphoblastic leukemia (T-ALL). The typical translocation partner is the NUP214 gene. BCR-ABL translocations are relatively rare in this entity. Furthermore, while there have been unique patterns of amplification noted among the NUP214-ABL fusion genes, there have been few such reports among cases with BCR-ABL fusion genes. Case presentation: Here we report a unique case of a 44-year old patient with T-ALL in which the blasts demonstrated a derivative chromosome 9 involving a 9;22 translocation and a dicentric Philadelphia chromosome 22 with a homogeneously staining region at the interface of the 9;22 translocation, leading to BCR-ABL1 gene amplification...
2017: Molecular Cytogenetics
https://www.readbyqxmd.com/read/29034366/a-phase-2-study-incorporating-sorafenib-into-the-chemotherapy-for-older-adults-with-flt3-mutated-acute-myeloid-leukemia-calgb-11001
#15
Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J Levis, Heidi D Klepin, Maria R Baer, Bayard L Powell, Peter Westervelt, Daniel J DeAngelo, Wendy Stock, Ben Sanford, William G Blum, Clara D Bloomfield, Richard M Stone, Richard A Larson
The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 ( FLT3 )-mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin and cytarabine-based induction and consolidation chemotherapy and was also continued for 12 months of maintenance therapy. The primary end point of the study was overall survival (OS) at 1 year in the FLT3 internal tandem duplication (FLT3-ITD) cohort...
January 24, 2017: Blood Advances
https://www.readbyqxmd.com/read/29023215/cost-effectiveness-analysis-of-monthly-zoledronic-acid-zoledronic-acid-every-3-months-and-monthly-denosumab-in-women-with-breast-cancer-and-skeletal-metastases-calgb-70604-alliance
#16
RANDOMIZED CONTROLLED TRIAL
Charles L Shapiro, James P Moriarty, Stacie Dusetzina, Andrew L Himelstein, Jared C Foster, Stephen S Grubbs, Paul J Novotny, Bijan J Borah
Purpose Skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, or the necessity for radiation or surgery to bone metastasis cause considerable morbidity, decrements in quality of life, and costs to the health care system. The results of a recent large randomized trial (Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs. We sought to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases...
December 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28982874/impact-of-calgb-9343-trial-and-sociodemographic-variation-on-patterns-of-adjuvant-radiation-therapy-practice-for-elderly-women-%C3%A2-70-years-with-stage-i-estrogen-receptor-positive-breast-cancer-analysis-of-the-national-cancer-data-base
#17
Quyen D Chu, Meijiao Zhou, Kaelen L Medeiros, Prakash Peddi, Xiao Cheng Wu
BACKGROUND: The Cancer and Leukemia Group B (CALGB) 9343 trial demonstrated that adjuvant radiation therapy (RT) can be omitted in women 70 years or older, with small (≤2 cm), negative lymph nodes, estrogen receptor (ER)-positive breast cancer. We examined whether RT usage following the CALGB publication had decreased over time and evaluated sociodemographic and clinical factors associated with RT omission. MATERIALS AND METHODS: From the National Cancer Data Base, we analyzed a cohort of 120,308 women aged 70 years or older with stage I, ER-positive breast cancer who underwent lumpectomy...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28976791/adjuvant-chemoradiotherapy-with-epirubicin-cisplatin-and-fluorouracil-compared-with-adjuvant-chemoradiotherapy-with-fluorouracil-and-leucovorin-after-curative-resection-of-gastric-cancer-results-from-calgb-80101-alliance
#18
RANDOMIZED CONTROLLED TRIAL
Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, Joel E Tepper, Xing Ye, Richard S Swanson, Peter C Enzinger, Daniel G Haller, Tomislav Dragovich, Steven R Alberts, Georg A Bjarnason, Christopher G Willett, Leonard L Gunderson, Richard M Goldberg, Alan P Venook, David Ilson, Eileen O'Reilly, Kristen Ciombor, David J Berg, Jeffrey Meyerhardt, Robert J Mayer
Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with a potentially more active systemic therapy could further improve overall survival...
November 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28945884/a-phase-ii-trial-of-lenalidomide-plus-rituximab-in-previously-untreated-follicular-non-hodgkin-s-lymphoma-nhl-calgb-50803-alliance
#19
MULTICENTER STUDY
P Martin, S-H Jung, B Pitcher, N L Bartlett, K A Blum, T Shea, E D Hsi, J Ruan, S E Smith, J P Leonard, B D Cheson
Background: This multicenter, phase II trial tested the tolerability and efficacy of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma (FL). Patients and methods: Patients with grade 1-3a FL, stage 3-4 or bulky stage 2, FL international prognostic index (FLIPI) 0-2, and no prior therapy were eligible to receive rituximab 375 mg/m2 weekly during cycle 1 and day 1 of cycles 4, 6, 8, and 10, plus lenalidomide 20-25 mg on days 1-21 for twelve 28-day cycles...
November 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28842510/impact-of-therapy-on-genomics-and-transcriptomics-in-high-risk-prostate-cancer-treated-with-neoadjuvant-docetaxel-and-androgen-deprivation-therapy
#20
Himisha Beltran, Alexander W Wyatt, Edmund C Chedgy, Adam Donoghue, Matti Annala, Evan W Warner, Kevin Beja, Michael Sigouros, Fan Mo, Ladan Fazli, Colin C Collins, James Eastham, Michael Morris, Mary-Ellen Taplin, Andrea Sboner, Susan Halabi, Martin E Gleave
Purpose: The combination of docetaxel chemotherapy and androgen deprivation therapy (ADT) has become a standard treatment for patients with metastatic prostate cancer. The recently accrued phase III CALGB 90203 trial was designed to investigate the clinical effectiveness of this treatment approach earlier in the disease. Specimens from this trial offer a unique opportunity to interrogate the acute molecular response to docetaxel and ADT and identify potential biomarkers. Experimental Design: We evaluated baseline clinical data, needle biopsies, and radical prostatectomy (RP) specimens from 52 (of 788) patients enrolled on CALGB 90203 at one high volume center...
November 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
13247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"